| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/14/2006 | WO2006003471A3 Process for the preparation of pramipexole by chiral chromatography |
| 09/14/2006 | WO2005105120A3 Pharmaceutical combination, active on central nervous system (cns) and set of pharmaceuticals; method of treatment of cns-disorders; means facilitating penetration of the hematoencephalic barrier; pharmaceutical means for endonasal administration |
| 09/14/2006 | US20060205967 Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates |
| 09/14/2006 | US20060205956 Salt formation |
| 09/14/2006 | US20060205801 Crystal and process for producing the same |
| 09/14/2006 | US20060205796 Method for treating pain or pruritis by administering opinoid receptor agonist comprising 2-phenylbenzothiazoling derivative |
| 09/14/2006 | US20060205786 New use of iloperidone |
| 09/14/2006 | US20060205785 Fused ring compounds substituted with a 8-azabicyclo[3.2.1]octane(cyclo)alkylene group, including benzothiazolones, e.g., 3-[3-(3-Propyl-8-aza-bicyclo[3.2.1]oct-8-yl)-propyl]-3H-benzothiazol-2-one; highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes |
| 09/14/2006 | US20060205774 4-(4-(Heterocyclylakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's |
| 09/14/2006 | US20060205770 Acid addition salts such as (-)-(3R)-quinuclidin-3-yl(1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate (-)-(2S,3S)-tartrate; for treatment of various M3 receptor-mediated diseases such as urinary incontinence, respiratory diseases such as chronic obstructive pulmonary disease |
| 09/14/2006 | US20060205763 For therapy and prophylaxis of cardiovascular diseases, diabetes, diabetes- associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders |
| 09/14/2006 | US20060205762 For therapy and prophylaxis of cardiovascular diseases, diabetes, diabetes- associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders |
| 09/14/2006 | US20060205754 Combination of a serotonin reuptake inhibitors and agomelatine |
| 09/14/2006 | US20060205750 Cardiovascular disorders; central nervous system disorders; metabolic diseases; therapy for eating disorders; trans-2-(2-fluorophenyl)-8-[3'-oxospiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-yl]purine |
| 09/14/2006 | US20060205745 Microcrystal |
| 09/14/2006 | US20060205734 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 09/14/2006 | US20060205722 Such as N-{1-[2-(1,3-dioxan-2-yl)ethyl]piperidin-4-yl}-N-(4-fluorobenzyl)-2-[4-(2-hydroxy-2-methylpropoxy)phenyl]acetamide; selective inverse agonists of 5-HT2A receptor with minimal monamine receptors subtype activity; antipsychotics with reduced side effects |
| 09/14/2006 | US20060205721 3-(Phenyl),5-(3-carmoylphenyl)-amino)-3H-V-triazolo(4,5-D)pyrimidine; bipolar disorder, antidepressants; antidiabetic agents; Alzheimer's disease; blood disorders; dementia; parkinson's disease; neurodegenerative diseases; genetic disorders; muscular disorders; antiinflammatory/anticarcinogenic agents |
| 09/14/2006 | US20060205715 6-(8-Pentylamino-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-nicotinamide; increase metabolic energy consumption, and reduction of weight; obesity, antidiabetic agent, eating disorders; antidepressant, anxiolytic agent |
| 09/14/2006 | US20060205712 e.g. N-[2-[4-(2-(S)-amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl -quinolin-8-yloxy-methyl)-benzensulfonamide trifluoroacetate; antiinflammatory agent; asthma, chronic bronchitis, allergic rhinitis, obstructive pulmonary disease (COPD) |
| 09/14/2006 | US20060205710 Spiroazacyclic compounds as monoamine receptor modulators |
| 09/14/2006 | US20060205708 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors |
| 09/14/2006 | US20060205707 adenosine triphosphate inhibitors used for the treatment of cancer; anticarcinogenic agents |
| 09/14/2006 | US20060205696 [[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain |
| 09/14/2006 | US20060205690 Glycosaminoglycans correct emotional dysfunctions without altering the normal state of consciousness, because of their ability to prevent or reduce the alteration (fluidity)of the extracellular matrix (ECM) in the brain; depolymerized sulfates of dermatan, chondroitin, heparin, keratin; psychosis |
| 09/14/2006 | US20060205665 Non-basic amino acid sequence transporter peptide conjugated to biological effector; translocation across the membrane of eukaryotic cells |
| 09/14/2006 | US20060205659 Peptide radical having 5-25 amino acids with its N-terminus capped with a monoester of fumaric acid; used to treat autoimmune diseases, mitochondrial diseases, and NF-kappaB mediated diseases and in transplantation medicine |
| 09/14/2006 | US20060205655 Nucleic acids encoding (poly) peptides having CHIPS activity |
| 09/14/2006 | US20060205074 Neural progenitor cells derived from whole bone marrow |
| 09/14/2006 | US20060205021 Mammalian IAP gene family, primers, probes and detection methods |
| 09/14/2006 | US20060205018 Polypeptides which have zinc metalloprotease activities and are referred to as IGS5, and polynucleotides encoding such polypeptides; use in therapy |
| 09/14/2006 | US20060204593 Superoxide anion decomposing agent |
| 09/14/2006 | US20060204587 Use of film coating as taste-masking coating of oral dosage forms |
| 09/14/2006 | US20060204485 Probiotics in the treatment of atypical depression and other disorders characterised by hypothalamic pitiuitary-ardrenal axis over activity |
| 09/14/2006 | US20060204449 Nasal pharmaceutical composition of piribedil |
| 09/14/2006 | CA2604071A1 Antipruritic agent for pruritus caused by multiple sclerosis |
| 09/14/2006 | CA2601279A1 Formulation for aviptadil |
| 09/14/2006 | CA2600475A1 Heteroarylsulfonyl stilbenes as 5-ht2a antagonists |
| 09/14/2006 | CA2600254A1 Benzoxazocines and their therapeutic use |
| 09/14/2006 | CA2600169A1 Pyrazine -2-carboxamide derivatives as mglur5 antagonists |
| 09/14/2006 | CA2600093A1 Proteomic methods using sart stressed animals |
| 09/14/2006 | CA2600067A1 Treatment of amyotrophic lateral sclerosis with pyrimethamine and analogues 6 |
| 09/14/2006 | CA2600064A1 Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues6 |
| 09/14/2006 | CA2599974A1 Pyridine-2-carboxamide derivatives as mglur5 antagonists |
| 09/14/2006 | CA2599937A1 Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
| 09/14/2006 | CA2599872A1 Novel salt of quinuclidine derivative |
| 09/14/2006 | CA2599721A1 Pharmaceutical compositions for the treatment and/or prevention of depression |
| 09/14/2006 | CA2599699A1 Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| 09/14/2006 | CA2599547A1 Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| 09/14/2006 | CA2599511A1 2-(4-oxo-4h-quinazolin-3-yl) acetamides and their use as vasopressin v3 antagonists |
| 09/14/2006 | CA2599186A1 Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists |
| 09/14/2006 | CA2599125A1 Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
| 09/14/2006 | CA2598530A1 Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists |
| 09/14/2006 | CA2597255A1 Natural ligand of g protein coupled receptor rcc356 and uses thereof |
| 09/13/2006 | EP1700921A2 Regulation of a human asparagine-hydroxylase |
| 09/13/2006 | EP1700918A2 Activatable recombinant neurotoxins |
| 09/13/2006 | EP1700858A1 Salts of a quinuclidine derivative as muscarinic M3 receptor antagonists |
| 09/13/2006 | EP1700851A1 Crystalline citalopram diol intermediate alkali |
| 09/13/2006 | EP1700603A2 Immunostimulatory nucleic acids |
| 09/13/2006 | EP1700601A2 Use of dextromethorphan and an oxidase inhibitor for weaning patients from narcotics and anti-despressants |
| 09/13/2006 | EP1700596A1 Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons |
| 09/13/2006 | EP1700121A2 Agonist anti-trkc antibodies and methods using same |
| 09/13/2006 | EP1699924A2 Antisense compounds targeted to connexins and methods of use thereof |
| 09/13/2006 | EP1699802A1 Nicotinic acetylcholine receptor ligands |
| 09/13/2006 | EP1699801A1 Nicotinic acetylcholine receptor ligands |
| 09/13/2006 | EP1699795A1 Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalklymine]-pyrimido[1,2a]pyrimidin-6-one derivatives |
| 09/13/2006 | EP1699789A2 Synthesis of a polymorph of 4-amino-5-chloro-2-methoxy-n-(1-azabicyclo[3.3.1]non-4-yl)benzamide hydrochloride hydrate |
| 09/13/2006 | EP1699787A1 Nicotinic acetylcholine receptor ligands |
| 09/13/2006 | EP1699786A1 Nicotinic acetylcholine receptor ligands |
| 09/13/2006 | EP1699785A2 3-quinuclidinyl amino-substituted biaryl derivatives |
| 09/13/2006 | EP1699779A1 1,2,3,4-tetrahydroisoquinoline derivatives, preparations thereof and uses thereof |
| 09/13/2006 | EP1699778A1 (4-phenylpiperazin-1-yl)acylpiperidine derivatives, preparation thereof and application of same in therapeutics |
| 09/13/2006 | EP1699759A1 Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| 09/13/2006 | EP1699758A1 Diphenylazetidinone derivates processing cholesterol absorption inhibitory activity |
| 09/13/2006 | EP1699489A2 Pharmaceutical composition of a sodium channel blocker and a selective serotonin uptake inhibitor |
| 09/13/2006 | EP1699488A2 Therapeutic combination for cognition enhancement and psychotic disorders |
| 09/13/2006 | EP1699470A2 Biological active blood serum obtained by electrostimulation |
| 09/13/2006 | EP1699468A1 Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis |
| 09/13/2006 | EP1699467A1 Aminoglycoside antibiotics for use as vap-1/ssao inhibitors |
| 09/13/2006 | EP1699465A1 Treatment |
| 09/13/2006 | EP1699463A1 Pharmaceutical composition for treating and preventing cancer comprising cinnamoni cortex extract and zizyphi fructus extract |
| 09/13/2006 | EP1699454A1 Pyrazole derivatives and use thereof as orexin receptor antagonists |
| 09/13/2006 | EP1699450A2 Co-administration of dopamine-receptor binding compounds |
| 09/13/2006 | EP1699438A2 Pharmaceutical preparation containing gabapentin |
| 09/13/2006 | EP1626726B1 Use of lornoxicam or lornoxicam analogue compounds |
| 09/13/2006 | EP1625152B1 Peptides modulating the activity of the engrailed transcription factor |
| 09/13/2006 | EP1532145B1 Pyrazole compositions useful as inhibitors of gsk-3 |
| 09/13/2006 | EP1497274B1 Terphenyl derivatives, preparation thereof, compositions containing same |
| 09/13/2006 | EP1442050B1 Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 09/13/2006 | EP1406881B1 11-piperazinyldibenzo(b,f)(1,4)oxazepines and thiazepines as atypical antipsychotic agents having low affinity for the d2 receptor |
| 09/13/2006 | EP1389206B1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 09/13/2006 | EP1339840B1 Schizophrenia-related voltage-gated ion channel gene and protein |
| 09/13/2006 | EP1305635B1 Methods to identify compounds that modulate rage |
| 09/13/2006 | EP1305406B1 Modulation of gamma-secretase activity |
| 09/13/2006 | EP1282643B1 Anti-inflammatory compounds and uses thereof |
| 09/13/2006 | EP1237888B1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 09/13/2006 | EP1230215B1 Pyrrole derivatives as phosphodiesterase vii inhibitors |
| 09/13/2006 | EP1218358B1 Therapeutic quinazoline compounds |
| 09/13/2006 | CN1832946A Process for producing imide compound |
| 09/13/2006 | CN1832945A Diphenylpyridine derivatives, preparation and therapeutic application thereof |